ASCO 2022 | Characterization of the microbial resistome in a prospective trial of CBM588 in mRCC

Nazli Dizman, MD, Yale University School of Medicine, New Haven, CT, discusses the results of study characterizing the microbial resistome in a prospective trial of CBM588, a live bacterial product, in patients with metastatic renal cell carcinoma (mRCC). Patients enrolled received nivolumab and ipilimumab with or without CB588. Those who received CB588 exhibited an increased progression-free survival (PFS), demonstrating CBM588 in combination with antibiotic use may improve immune checkpoint blockade response. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.